Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V
In general, GLP-1 therapy may be considered for adults with obesity or overweight and certain weight-related health conditions, based on current clinical guidelines
Clinical trials evaluating semaglutide for weight management, including the pivotal STEP (Semaglutide Treatment Effect in People with obesity) programme published in the New England Journal of Medicine (2021), did not demonstrate a statistically significant increase in UTI incidence compared to placebo groups
Watch now The Biocare Blog Stay up to date with the latest health trends, expert insights, and tips for fitting Biocare into your wellness plan
However, extant human studies on BPC-157 as an anti-ulcer agent indicate a positive safety profile, with no toxicity reported [34]